Lenalidomide for the treatment of relapsed and refractory multiple myeloma

Niels W C J van de Donk, Gullu Gorgun, Richard W J Groen, Jana Jakubikova, Constantine S. Mitsiades, Teru Hideshima, Jacob Laubach, Inger S. Nijhof, Reinier A. Raymakers, Henk M. Lokhorst, Paul G. Richardson, Kenneth C. Anderson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with the introduction of bortezomib and thalidomide, lenalidomide has significantly improved the survival of patients with relapsed and refractory myeloma. The most common adverse events associated with lenalidomide include fatigue, skin rash, thrombocytopenia, and neutropenia. In addition, when lenalidomide is combined with dexamethasone or other conventional cytotoxic agents, there is an increase in the incidence of venous thromboembolic events. There is now evidence that continued treatment with lenalidomide has a significant impact on survival by improving the depth and duration of response. This highlights the value of adverse event management and appropriate dose adjustments to prevent toxicity, and of allowing continued treatment until disease progression. In this review, we will discuss the different lenalidomide-based treatment regimens for patients with relapsed/refractory myeloma. This is accompanied by recommendations of how to manage and prevent adverse events associated with lenalidomide-based therapy.

Original languageEnglish (US)
Pages (from-to)253-268
Number of pages16
JournalCancer Management and Research
Volume4
Issue number1
DOIs
StatePublished - Aug 13 2012
Externally publishedYes

Fingerprint

Multiple Myeloma
Thalidomide
Therapeutics
Survival
Cytotoxins
lenalidomide
Exanthema
Neutropenia
Thrombocytopenia
Dexamethasone
Fatigue
Disease Progression
Incidence
Neoplasms

Keywords

  • Immunomodulatory drugs
  • Lenalidomide
  • Multiple myeloma
  • Refractory disease
  • Relapse treatment

ASJC Scopus subject areas

  • Oncology

Cite this

van de Donk, N. W. C. J., Gorgun, G., Groen, R. W. J., Jakubikova, J., Mitsiades, C. S., Hideshima, T., ... Anderson, K. C. (2012). Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Management and Research, 4(1), 253-268. https://doi.org/10.2147/CMAR.S27087

Lenalidomide for the treatment of relapsed and refractory multiple myeloma. / van de Donk, Niels W C J; Gorgun, Gullu; Groen, Richard W J; Jakubikova, Jana; Mitsiades, Constantine S.; Hideshima, Teru; Laubach, Jacob; Nijhof, Inger S.; Raymakers, Reinier A.; Lokhorst, Henk M.; Richardson, Paul G.; Anderson, Kenneth C.

In: Cancer Management and Research, Vol. 4, No. 1, 13.08.2012, p. 253-268.

Research output: Contribution to journalArticle

van de Donk, NWCJ, Gorgun, G, Groen, RWJ, Jakubikova, J, Mitsiades, CS, Hideshima, T, Laubach, J, Nijhof, IS, Raymakers, RA, Lokhorst, HM, Richardson, PG & Anderson, KC 2012, 'Lenalidomide for the treatment of relapsed and refractory multiple myeloma', Cancer Management and Research, vol. 4, no. 1, pp. 253-268. https://doi.org/10.2147/CMAR.S27087
van de Donk NWCJ, Gorgun G, Groen RWJ, Jakubikova J, Mitsiades CS, Hideshima T et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Management and Research. 2012 Aug 13;4(1):253-268. https://doi.org/10.2147/CMAR.S27087
van de Donk, Niels W C J ; Gorgun, Gullu ; Groen, Richard W J ; Jakubikova, Jana ; Mitsiades, Constantine S. ; Hideshima, Teru ; Laubach, Jacob ; Nijhof, Inger S. ; Raymakers, Reinier A. ; Lokhorst, Henk M. ; Richardson, Paul G. ; Anderson, Kenneth C. / Lenalidomide for the treatment of relapsed and refractory multiple myeloma. In: Cancer Management and Research. 2012 ; Vol. 4, No. 1. pp. 253-268.
@article{3a6f9c53963943fa8ac6bf16acad4f1b,
title = "Lenalidomide for the treatment of relapsed and refractory multiple myeloma",
abstract = "Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with the introduction of bortezomib and thalidomide, lenalidomide has significantly improved the survival of patients with relapsed and refractory myeloma. The most common adverse events associated with lenalidomide include fatigue, skin rash, thrombocytopenia, and neutropenia. In addition, when lenalidomide is combined with dexamethasone or other conventional cytotoxic agents, there is an increase in the incidence of venous thromboembolic events. There is now evidence that continued treatment with lenalidomide has a significant impact on survival by improving the depth and duration of response. This highlights the value of adverse event management and appropriate dose adjustments to prevent toxicity, and of allowing continued treatment until disease progression. In this review, we will discuss the different lenalidomide-based treatment regimens for patients with relapsed/refractory myeloma. This is accompanied by recommendations of how to manage and prevent adverse events associated with lenalidomide-based therapy.",
keywords = "Immunomodulatory drugs, Lenalidomide, Multiple myeloma, Refractory disease, Relapse treatment",
author = "{van de Donk}, {Niels W C J} and Gullu Gorgun and Groen, {Richard W J} and Jana Jakubikova and Mitsiades, {Constantine S.} and Teru Hideshima and Jacob Laubach and Nijhof, {Inger S.} and Raymakers, {Reinier A.} and Lokhorst, {Henk M.} and Richardson, {Paul G.} and Anderson, {Kenneth C.}",
year = "2012",
month = "8",
day = "13",
doi = "10.2147/CMAR.S27087",
language = "English (US)",
volume = "4",
pages = "253--268",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Lenalidomide for the treatment of relapsed and refractory multiple myeloma

AU - van de Donk, Niels W C J

AU - Gorgun, Gullu

AU - Groen, Richard W J

AU - Jakubikova, Jana

AU - Mitsiades, Constantine S.

AU - Hideshima, Teru

AU - Laubach, Jacob

AU - Nijhof, Inger S.

AU - Raymakers, Reinier A.

AU - Lokhorst, Henk M.

AU - Richardson, Paul G.

AU - Anderson, Kenneth C.

PY - 2012/8/13

Y1 - 2012/8/13

N2 - Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with the introduction of bortezomib and thalidomide, lenalidomide has significantly improved the survival of patients with relapsed and refractory myeloma. The most common adverse events associated with lenalidomide include fatigue, skin rash, thrombocytopenia, and neutropenia. In addition, when lenalidomide is combined with dexamethasone or other conventional cytotoxic agents, there is an increase in the incidence of venous thromboembolic events. There is now evidence that continued treatment with lenalidomide has a significant impact on survival by improving the depth and duration of response. This highlights the value of adverse event management and appropriate dose adjustments to prevent toxicity, and of allowing continued treatment until disease progression. In this review, we will discuss the different lenalidomide-based treatment regimens for patients with relapsed/refractory myeloma. This is accompanied by recommendations of how to manage and prevent adverse events associated with lenalidomide-based therapy.

AB - Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with the introduction of bortezomib and thalidomide, lenalidomide has significantly improved the survival of patients with relapsed and refractory myeloma. The most common adverse events associated with lenalidomide include fatigue, skin rash, thrombocytopenia, and neutropenia. In addition, when lenalidomide is combined with dexamethasone or other conventional cytotoxic agents, there is an increase in the incidence of venous thromboembolic events. There is now evidence that continued treatment with lenalidomide has a significant impact on survival by improving the depth and duration of response. This highlights the value of adverse event management and appropriate dose adjustments to prevent toxicity, and of allowing continued treatment until disease progression. In this review, we will discuss the different lenalidomide-based treatment regimens for patients with relapsed/refractory myeloma. This is accompanied by recommendations of how to manage and prevent adverse events associated with lenalidomide-based therapy.

KW - Immunomodulatory drugs

KW - Lenalidomide

KW - Multiple myeloma

KW - Refractory disease

KW - Relapse treatment

UR - http://www.scopus.com/inward/record.url?scp=84930476992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930476992&partnerID=8YFLogxK

U2 - 10.2147/CMAR.S27087

DO - 10.2147/CMAR.S27087

M3 - Article

VL - 4

SP - 253

EP - 268

JO - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

IS - 1

ER -